Skip to main content
. 2021 Jun 10;125(5):725–733. doi: 10.1038/s41416-021-01431-9

Fig. 1. Flow diagram illustrating all the biomarkers of the Coca Colon cohort study.

Fig. 1

*Patients for which the results of circulating markers and 12-week evaluation were available. CA19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, cfDNA cell-free DNA, CTC circulating tumour cells, ctDNA circulating tumour DNA, WT wild type. †Kinetics were estimated for living non-progressive patients having a positive baseline value and two or three further measures at fourth cycle. ‡Only CTC baseline-positive patients underwent kinetic analysis.